Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
NEW YORK, Jan. 12, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Osiris Therapeutics, Inc. (“Osiris Therapeutics”) (NASDAQ:OSIR) between May 12, 2014 through November 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. If you purchased or otherwise acquired Osiris Therapeutics between May 12, 2014 and November 20, 2015, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/osiris-therapeutics-osir
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
